Roche's Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients with Hemophilia A Without Factor VIII Inhibitors
Shots:
- The approval is based on HAVEN 3 & 4 studies. The P-III HAVEN 3 study results assessing Hemlibra (qw/q2w) vs episodic FVIII & no prophylaxis in 152 patients with hemophilia A without FVIII inhibitors prior treated with episodic/prophylactic treatment with FVIII- resulted in reduction in treated bleeds (96%/97%); zero treated bleeds (55.6% / 60% vs 0%); zero treated target joint bleed (69.4%/ 77.1% vs 27.8%)
- The HAVEN IV study results involves assessing of Hemlibra in 41 patients with hemophilia A with/out FVIII inhibitors- prior treated with episodic/prophylactic treatment with FVIII or bypassing agents/FVIII- resulted in 52.8%- 27.8%- 83.3%- 69.4% & 83.3% experiencing zero bleeds including all treated bleed- all bleed- treated spontaneous bleeds- treated joint bleeds & treated joint bleeds respectively
- Hemlibra (SC) is mAb targeting IgG4- being co-developed by Chugai & Roche and has received approval in the US- EU for hemophilia A with and without factor VIII inhibitors
Ref: PRNewswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com